Sociedad Americana de Hirudoterapia

A novel Toll like receptor with two TIR domains (HcToll-2) is involved in regulation of antimicrobial peptide gene expression of Hyriopsis cumingii.

Research article published in Developmental and comparative immunology (2014)

Última actualización: June 18, 2026Revisado por: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: In vitro / laboratoryResistencia antimicrobianaDesarrollo de fármacosGenómica y proteómicaRen Q et al. · Developmental and comparative immunology, 2014

Abstract

Animal Toll-like receptors (TLRs) are involved in innate immunity. Toll proteins are generally transmembrane proteins. In this study, an atypical Toll-like receptor (HcToll-2) was identified from the triangle-shell pearl mussel Hyriopsis cumingii, which belongs to phylum Mollusca. Unlike the typical Toll like receptors with extracellular leucine-rich repeats (LRRs), transmembrane, and intracellular Toll/interleukin-1 receptor (TIR) domains, HcToll-2 has two homologous TIR domains located at the C-terminal (designated as HcTIR1 and HcTIR2) and lacks a transmembrane domain. Phylogenetic analysis showed that HcTIR1 was clustered with TIR of sea anemone Toll, and HcTIR2 was clustered with TIR of Drosophila Toll. HcToll-2 mRNA could be detected in the hepatopancreas and was upregulated after challenge with Escherichia coli and Staphylococcus aureus. Recombinant HcLRR protein with GST tag could bind to bacteria and also to LPS and PGN. Over-expression of both HcTIR1 and HcTIR2 induced drosomycin genes in Drosophila S2 cells. RNAi analysis showed that HcToll-2 was required for the expression of theromacin, which is a cysteine-rich antimicrobial peptide (AMP) gene. This research is the first report of an atypical Toll-like receptor HcToll-2 involved in antibacterial immunity through induction of AMP expression.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal ArticleResearch Support, Non-U.S. Gov't
Indexed MeSH termsAmino Acid SequenceAnimalsAntimicrobial Cationic PeptidesBase SequenceCell LineConsensus SequenceDrosophila melanogasterGram-Negative BacteriaGram-Positive BacteriaLipopolysaccharidesMolecular Sequence DataPhylogeny

Resumen

Animal Toll-like receptors (TLRs) are involved in innate immunity. Toll proteins are generally transmembrane proteins. In this study, an atypical Toll-like receptor (HcToll-2) was identified from the triangle-shell pearl mussel Hyriopsis cumingii, which belongs to phylum Mollusca.

Por qué esto importa para la hirudoterapia

Nota de nomenclatura/alcance: a pesar de figurar en un índice de investigación de la ASH, este estudio no trata sobre sanguijuelas en absoluto. Identifica y caracteriza un receptor tipo Toll atípico (HcToll-2) con dos dominios TIR y sin región transmembrana en el mejillón perlífero de agua dulce de concha triangular Hyriopsis cumingii (filo Mollusca), demostrando que su ARNm aumenta tras el desafío con Escherichia coli y Staphylococcus aureus y que es necesario para la expresión del péptido antimicrobiano theromacin. El único vínculo con la hirudoterapia es indirecto: theromacin se describió originalmente en una sanguijuela, y la biología de la inmunidad innata y los péptidos antimicrobianos de los invertebrados es parte de la razón por la que se estudian las secreciones de las sanguijuelas. Advertencia: se trata de un estudio preclínico/de inmunología molecular in vitro en un mejillón, no en una sanguijuela ni en ninguna especie medicinal de Hirudo, y no hace ninguna afirmación sobre la hirudoterapia; su relevancia para el contexto de la terapia con sanguijuelas es mínima y no debe exagerarse.

Citación

A novel Toll like receptor with two TIR domains (HcToll-2) is involved in regulation of antimicrobial peptide gene expression of Hyriopsis cumingii.

Ren Q et al. · Developmental and comparative immunology, 2014

Contexto clínico relacionado

Añadido a la biblioteca ASH: May 28, 2026 · Última actualización del sitio: June 18, 2026

Este sitio web proporciona información educativa y no constituye consejo médico, diagnóstico ni recomendaciones de tratamiento. La terapia con sanguijuelas medicinales conlleva riesgos clínicamente significativos y debe ser realizada únicamente por profesionales calificados bajo protocolos aprobados institucionalmente. La autorización 510(k) de la FDA para sanguijuelas medicinales se limita a indicaciones específicas; las discusiones sobre uso investigativo y fuera de indicación se señalan correspondientemente. Para orientación médica específica, consulte a un profesional de salud calificado.